Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Carrier screening for genetic disease in the Ashkenazi Jewish population

Ashley S Roman, MD, MPH
Section Editor
Louise Wilkins-Haug, MD, PhD
Deputy Editor
Vanessa A Barss, MD, FACOG


When a mutant allele is introduced into a community that procreates mostly among themselves, the frequency of the allele will become higher in the community than in the general population. As a result, the community will have a higher incidence of rare genetic disorders associated with the allele, a situation known as the "founder effect." The increased incidence of Tay-Sachs disease and several other disorders (table 1) among descendants of Ashkenazi Jews is an example of this phenomenon. Because these serious disorders are more common among Ashkenazi Jews, genetic carrier screening programs have been successful and have a high acceptance rate in this population [1,2].


Rationale — Ashkenazi Jews are descendants of Jews from Central and Eastern Europe (eg, Germany, France, Poland, Hungary, Russia, Ukraine, Lithuania), while Sephardic Jews are descendants of Jews from Spain, Portugal, and North Africa. Individuals of Ashkenazi Jewish descent are an example of the founder effect. One in four to one in five individuals of Ashkenazi Jewish descent carry a mutation for one of the autosomal recessive disorders included in a group of disorders sometimes called "Jewish genetic disorders" [3]. Some of these disorders have a high incidence, primarily among individuals of Ashkenazi Jewish descent (eg, Tay-Sachs disease); for many of the disorders (eg, familial dysautonomia), the mutation has been identified almost exclusively in these individuals [1]. Some of the disorders (eg, cystic fibrosis) are also common in other high-risk ethnic groups. Although the disorders can also affect Sephardic Jews, non-Jews, and Jews from mixed backgrounds, they are less prevalent in these populations. Most of the disorders are severely disabling, untreatable, and associated with a shortened life expectancy.

Carrier screening in this population is performed to identify asymptomatic individuals who carry genetic mutations causing any of the genetic disorders more common in descendants of Ashkenazi Jews. If both parents are carriers of a mutation causing the same disorder, there is a one in four chance their offspring will inherit two copies of the mutation (one from each parent) and will be susceptible to developing the phenotype. Identification of these couples gives them the opportunity to pursue reproductive options to avoid an affected pregnancy, prepare for the birth of an affected child, or terminate an affected pregnancy. Negative test results relieve some of the anxiety associated with pregnancy. (See 'Post-test management' below.)

What to screen for — Laboratories offer screening panels that test for several disorders as a group in a single multiplex assay. The number of disorders included in panels for individuals of Ashkenazi Jewish descent is variable (eg, 4, 9, 11, or more), based in part on the carrier frequency in this population and the severity of the phenotype. Some panels include disorders that are rare even in this population if only a few mutations account for the majority of disease.

The American College of Medical Genetics and Genomics (ACMG) recommends routinely offering carrier screening for the following nine disorders: Tay-Sachs disease, Canavan disease, cystic fibrosis, familial dysautonomia, mucolipidosis IV, Niemann Pick disease type A, Fanconi anemia group C, Bloom Syndrome, and Gaucher disease, because of carrier detection rates ≥90 percent and population carrier frequency of ≥1 percent (table 1) [3].


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Mar 2017. | This topic last updated: Apr 14, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Eng CM, Schechter C, Robinowitz J, et al. Prenatal genetic carrier testing using triple disease screening. JAMA 1997; 278:1268.
  2. Kronn D, Jansen V, Ostrer H. Carrier screening for cystic fibrosis, Gaucher disease, and Tay-Sachs disease in the Ashkenazi Jewish population: the first 1000 cases at New York University Medical Center, New York, NY. Arch Intern Med 1998; 158:777.
  3. Gross SJ, Pletcher BA, Monaghan KG, Professional Practice and Guidelines Committee. Carrier screening in individuals of Ashkenazi Jewish descent. Genet Med 2008; 10:54.
  4. Committee Opinion No. 691: Carrier Screening for Genetic Conditions. Obstet Gynecol 2017; 129:e41.
  5. Grody WW, Thompson BH, Gregg AR, et al. ACMG position statement on prenatal/preconception expanded carrier screening. Genet Med 2013; 15:482.
  6. www.geneticdiseasefoundation.org (Accessed on May 01, 2011).
  7. Hoffman JD, Park JJ, Schreiber-Agus N, et al. The Ashkenazi Jewish carrier screening panel: evolution, status quo, and disparities. Prenat Diagn 2014; 34:1161.
  8. Committee Opinion No. 690: Carrier Screening in the Age of Genomic Medicine. Obstet Gynecol 2017; 129:e35.
  9. Wallerstein R, Starkman A, Jansen V. Carrier screening for Gaucher disease in couples of mixed ethnicity. Genet Test 2001; 5:61.
  10. Schneider A, Nakagawa S, Keep R, et al. Population-based Tay-Sachs screening among Ashkenazi Jewish young adults in the 21st century: Hexosaminidase A enzyme assay is essential for accurate testing. Am J Med Genet A 2009; 149A:2444.
  11. Monaghan KG, Feldman GL, Palomaki GE, et al. Technical standards and guidelines for reproductive screening in the Ashkenazi Jewish population. Genet Med 2008; 10:57.
  12. Park NJ, Morgan C, Sharma R, et al. Improving accuracy of Tay Sachs carrier screening of the non-Jewish population: analysis of 34 carriers and six late-onset patients with HEXA enzyme and DNA sequence analysis. Pediatr Res 2010; 67:217.
  13. Shahrabani-Gargir L, Shomrat R, Yaron Y, et al. High frequency of a common Bloom syndrome Ashkenazi mutation among Jews of Polish origin. Genet Test 1998; 2:293.
  14. Li L, Eng C, Desnick RJ, et al. Carrier frequency of the Bloom syndrome blmAsh mutation in the Ashkenazi Jewish population. Mol Genet Metab 1998; 64:286.
  15. Roa BB, Savino CV, Richards CS. Ashkenazi Jewish population frequency of the Bloom syndrome gene 2281 delta 6ins7 mutation. Genet Test 1999; 3:219.
  16. German J. Bloom's syndrome: Incidence, age of onset, and types of leukemia in the Bloom's Syndrome Registry. In: Genetics of hematological disorders, Bartsocas CS, Loukopoulos D (Eds), Hemisphere Publishers, Washington, DC 1992. p.241.
  17. TALLAN HH, MOORE S, STEIN WH. N-Acetyl-L-aspartic acid in brain. J Biol Chem 1956; 219:257.
  18. Kronn D, Oddoux C, Phillips J, Ostrer H. Prevalence of Canavan disease heterozygotes in the New York metropolitan Ashkenazi Jewish population. Am J Hum Genet 1995; 57:1250.
  19. Matalon RM, Michals-Matalon K. Spongy degeneration of the brain, Canavan disease: biochemical and molecular findings. Front Biosci 2000; 5:D307.
  20. Sugarman EA, Allitto BA. Carrier testing for seven diseases common in the Ashkenazi Jewish population, implications for counseling and testing. Obstet Gynecol 2001; 97:S38.
  21. Matalon R, Michals K, Sebesta D, et al. Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease. Am J Med Genet 1988; 29:463.
  22. Adachi M, Torii J, Schneck L, Volk BW. Electron microscopic and enzyme histochemical studies of the cerebellum in spongy degeneration (van Bogaert and Bertrans type). Acta Neuropathol 1972; 20:22.
  23. Al-Dirbashi OY, Kurdi W, Imtiaz F, et al. Reliable prenatal diagnosis of Canavan disease by measuring N-acetylaspartate in amniotic fluid using liquid chromatography tandem mass spectrometry. Prenat Diagn 2009; 29:477.
  24. Matalon R, Michals-Matalon K. Canavan disease. In: Pagon RA, Adam MP, Ardinger HH, et al, (Eds), GeneReviews [Internet], University of Washington, Seattle, 1993-2015.
  25. Abeliovich D, Lavon IP, Lerer I, et al. Screening for five mutations detects 97% of cystic fibrosis (CF) chromosomes and predicts a carrier frequency of 1:29 in the Jewish Ashkenazi population. Am J Hum Genet 1992; 51:951.
  26. Eng CM, Burgert TS, Schecter C, et al. Multiplex genetic testing in the Ashkenazi Jewish population. Am J Hum Genet 1995; 57:A57.
  27. Leib JR, Gollust SE, Hull SC, Wilfond BS. Carrier screening panels for Ashkenazi Jews: is more better? Genet Med 2005; 7:185.
  28. Lehavi O, Aizenstein O, Bercovich D, et al. Screening for familial dysautonomia in Israel: evidence for higher carrier rate among Polish Ashkenazi Jews. Genet Test 2003; 7:139.
  29. Maayan C, Kaplan E, Shachar S, et al. Incidence of familial dysautonomia in Israel 1977-1981. Clin Genet 1987; 32:106.
  30. Blumenfeld A, Slaugenhaupt SA, Liebert CB, et al. Precise genetic mapping and haplotype analysis of the familial dysautonomia gene on human chromosome 9q31. Am J Hum Genet 1999; 64:1110.
  31. Slaugenhaupt SA, Blumenfeld A, Gill SP, et al. Tissue-specific expression of a splicing mutation in the IKBKAP gene causes familial dysautonomia. Am J Hum Genet 2001; 68:598.
  32. Rosenberg PS, Tamary H, Alter BP. How high are carrier frequencies of rare recessive syndromes? Contemporary estimates for Fanconi Anemia in the United States and Israel. Am J Med Genet A 2011; 155A:1877.
  33. Meissner T, Wendel U, Burgard P, et al. Long-term follow-up of 114 patients with congenital hyperinsulinism. Eur J Endocrinol 2003; 149:43.
  34. Zuckerman S, Lahad A, Shmueli A, et al. Carrier screening for Gaucher disease: lessons for low-penetrance, treatable diseases. JAMA 2007; 298:1281.
  35. Beutler E. Carrier screening for Gaucher disease: more harm than good? JAMA 2007; 298:1329.
  36. Beutler E, Gelbart T, Kuhl W, et al. Identification of the second common Jewish Gaucher disease mutation makes possible population-based screening for the heterozygous state. Proc Natl Acad Sci U S A 1991; 88:10544.
  37. Horowitz M, Tzuri G, Eyal N, et al. Prevalence of nine mutations among Jewish and non-Jewish Gaucher disease patients. Am J Hum Genet 1993; 53:921.
  38. Tsuji S, Martin BM, Barranger JA, et al. Genetic heterogeneity in type 1 Gaucher disease: multiple genotypes in Ashkenazic and non-Ashkenazic individuals. Proc Natl Acad Sci U S A 1988; 85:2349.
  39. Barranger JA, Ginns EI. Glucosylcerimidelipidoses: Gaucher disease. In: The metabolic basis of inherited disease, 6th, Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw Hill, 1989. p.1677.
  40. Zimran A, Elstein D, Abrahamov A, et al. Prenatal molecular diagnosis of Gaucher disease. Prenat Diagn 1995; 15:1185.
  41. Ramsay SL, Maire I, Bindloss C, et al. Determination of oligosaccharides and glycolipids in amniotic fluid by electrospray ionisation tandem mass spectrometry: in utero indicators of lysosomal storage diseases. Mol Genet Metab 2004; 83:231.
  42. Kishnani PS, Austin SL, Abdenur JE, et al. Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics. Genet Med 2014; 16:e1.
  43. Ekstein J, Rubin BY, Anderson SL, et al. Mutation frequencies for glycogen storage disease Ia in the Ashkenazi Jewish population. Am J Med Genet A 2004; 129A:162.
  44. Caridi G, Dagnino M, Rossi A, et al. Nephronophthisis type 1 deletion syndrome with neurological symptoms: prevalence and significance of the association. Kidney Int 2006; 70:1342.
  45. Parisi MA, Bennett CL, Eckert ML, et al. The NPHP1 gene deletion associated with juvenile nephronophthisis is present in a subset of individuals with Joubert syndrome. Am J Hum Genet 2004; 75:82.
  46. Tory K, Lacoste T, Burglen L, et al. High NPHP1 and NPHP6 mutation rate in patients with Joubert syndrome and nephronophthisis: potential epistatic effect of NPHP6 and AHI1 mutations in patients with NPHP1 mutations. J Am Soc Nephrol 2007; 18:1566.
  47. Nellis MM, Danner DJ. Gene preference in maple syrup urine disease. Am J Hum Genet 2001; 68:232.
  48. Nellis MM, Kasinski A, Carlson M, et al. Relationship of causative genetic mutations in maple syrup urine disease with their clinical expression. Mol Genet Metab 2003; 80:189.
  49. Bassi MT, Manzoni M, Monti E, et al. Cloning of the gene encoding a novel integral membrane protein, mucolipidin-and identification of the two major founder mutations causing mucolipidosis type IV. Am J Hum Genet 2000; 67:1110.
  50. Bargal R, Avidan N, Olender T, et al. Mucolipidosis type IV: novel MCOLN1 mutations in Jewish and non-Jewish patients and the frequency of the disease in the Ashkenazi Jewish population. Hum Mutat 2001; 17:397.
  51. Slaugenhaupt SA, Acierno JS Jr, Helbling LA, et al. Mapping of the mucolipidosis type IV gene to chromosome 19p and definition of founder haplotypes. Am J Hum Genet 1999; 65:773.
  52. Kaback M, Lim-Steele J, Dabholkar D, et al. Tay-Sachs disease--carrier screening, prenatal diagnosis, and the molecular era. An international perspective, 1970 to 1993. The International TSD Data Collection Network. JAMA 1993; 270:2307.
  53. Bach G, Tomczak J, Risch N, Ekstein J. Tay-Sachs screening in the Jewish Ashkenazi population: DNA testing is the preferred procedure. Am J Med Genet 2001; 99:70.